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Abstract
Ovarian cancer represents the most lethal of the gynecological neoplasms. The molecular and
genetic events associated with early ovarian oncogenesis are still largely unknown, thus
contributing to the lack of reliable biomarkers for disease detection. Since the majority of ovarian
tumors are diagnosed at an advanced stage, the availability of early ovarian cancer tissue samples
for molecular analyses is very limited. In this review, problems encountered in the study of early
ovarian cancer are presented, along with the controversies concerning precursor lesions and
stepwise progression towards ovarian malignancy. Experimental modeling in the development of
ovarian cancer is also described, as well as genetic and epigenetic alterations associated with early
ovarian cancer. Lastly, examples of technological advances in the study of early ovarian cancer are
discussed. Hopefully, the increasing knowledge about molecular and genetic events involved in the
early stages of ovarian tumorigenesis will provide the basis for management of ovarian cancer in
the future.
Introduction
The term ovarian cancer applies in general to malignant
tumors arising from the modified peritoneal mesothe-
lium that covers the surface of the ovary [1]. These epithe-
lial ovarian cancers (EOC) make up 90% of all human
ovarian malignant tumors and display a wide range of his-
tological features, usually recapitulating the morphology
of the endocervix, endometrium, or Fallopian tubes that
are embriologically related to the surface epithelium [2,3].
Ovarian cancer is the most prevalent cause of death from
a gynecological malignancy among women in the West-
ern world, primarily reflecting the fact that it produces
vague symptoms, resulting in diagnosis at an advanced
stage [4]. In contrast to breast cancer, where most cases are
detected at an early stage, only 25% of ovarian cancers are
diagnosed at stage I, when the cure rate is almost 90%. The
cure rate for ovarian cancer diagnosed at an advanced
stage is less than 20% [5]. Ovarian cancer mortality has
not significantly decreased due to our poor understanding
of the underlying biology, which in turn has contributed
to a lack of reliable biomarkers for disease detection.
Therefore, endeavors to improve survival continue to
focus on the development of novel chemotherapeutic
agents and strategies for earlier detection and prevention
of this devastating disease [6].
Problems encountered in the study of early 
ovarian cancer
There are many difficulties associated with studying early
events in ovarian oncogenesis. Only few suitable in vitro
and  in vivo models of ovarian neoplasms have been
described thus far. The most commonly used experimen-
tal animals do not develop EOC. They instead get non-
epithelial (sex cord-stromal or germ cell) ovarian tumors,
whose underlying biology is ultimately different from that
of EOC. The methodology to culture human ovarian sur-
face epithelium (OSE), which presumably gives rise to
EOC, has become accessible only recently [7,8]. Human
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OSE (HOSE) cells are especially fragile and, being easily
removed by handling the ovary or allowing it to dry, are
often absent in surgical samples, and thus unavailable for
consecutive molecular analyses. Hence, it is difficult to
attain HOSE cells, maintain them in tissue culture, and
analyze under standardized conditions. Despite these
experimental difficulties, the first transgenic mouse model
of EOC has been successfully described just recently [9].
The specific location of the ovary, deep in the pelvis,
excludes the use of invasive screening procedures. Conse-
quently, the vast majority of ovarian tumors available to
investigators through tumor banks come from patients
with advanced disease. The availability of early ovarian
cancer tissue samples, especially stage I, is unfortunately
very limited. Since there is little information on the
sequence of molecular and genetic alterations associated
with initiation and progression from early- to advanced-
stage ovarian cancer, an attempt will be made in this
review to summarize findings with regard to early events
in ovarian oncogenesis.
Genetics of ovarian cancer
It is well known that ovarian cancer has a large number of
genetic changes involving both activation of oncogenes
and loss of tumor-suppressor genes [10], thus complicat-
ing determination of the importance of an individual
gene's alteration. Even though numerous genes with
altered expression in EOC are under investigation world-
wide, only few are likely to be causal and will provide new
targets for diagnosis and therapy of this malignancy
[11,12]. The question of how to prove the causality of a
candidate gene to some aspect of the disease phenotype
will most probably be answered through the use of genet-
ically engineered mice. Ovarian cancer has been referred
to as very complex and heterogeneous. Because of this,
tumors with the same histological features that arise in
different patients may display diverse alterations with dif-
ferent patterns of oncogene activation or tumor-suppres-
sor gene loss [5].
Precursors of ovarian cancer
Contrary to the multistep progression model of colorectal
tumorigenesis, in which a distinct series of morphologi-
cally well-defined lesions have been described [13], the
ovarian cancer research community disagrees as to
whether inclusion cysts [14], benign ovarian tumors [15]
or borderline (low malignant potential) tumors [16] are
precursors of the EOC. Consequently, this controversy
about the source of EOC has hampered our efforts to dis-
sect and elucidate steps in ovarian oncogenesis. Although
the mainstream idea is that EOC's arise from the surface
epithelium, some investigators have questioned this
dogma by putting forward an alternative hypothesis that
EOC develops from the secondary Müllerian system
[3,17]. With regard to inclusion cysts, Salazar and col-
leagues had a unique opportunity to be among the first to
analyze in detail histological features of the ovaries pro-
phylactically removed from healthy women at an inher-
ited risk of ovarian malignancy [18]. In addition to
increased formation of inclusion cysts, many other abnor-
malities were observed in ovaries obtained in prophylactic
oophorectomies. Those include surface epithelial pseu-
dostratification, papillomatosis, deep cortical invagina-
tions of the surface epithelium, stromal abnormalities,
and ultrastructural changes in OSE cells. These histologi-
cal lesions were thought to be early substrates from which
ovarian cancer could develop.
It is also controversial whether benign, borderline and
malignant tumors are a part of a disease continuum of
stepwise progression toward ovarian cancer or if they rep-
resent separate disease entities, each arising de novo [17].
Certain molecular changes, such as telomerase expression,
alterations in DNA methylation levels and LOH are asso-
ciated with both borderline and malignant, but not
benign ovarian tumors, and will be discussed later on in
this review [19].
Epigenetic alterations in early ovarian cancer
Most recently, epigenetic changes have been recognized as
an important alternative mechanism of gene inactivation
in ovarian cancer. The evidence of hypermethylation of
the promoter region of BRCA1, which is known as breast
and ovarian cancer susceptibility gene and tumor-sup-
pressor gene involved in the maintenance of genomic
integrity, corroborates the view that this epigenetic altera-
tion may play a determinant role in inactivation of tumor-
suppressors and ultimately contributing to the initiation
or malignant progression of tumors. Consequently,
hypermethylated BRCA1 represents potential biological
marker for early ovarian cancer diagnosis and develop-
ment of methylation-targeted drugs for its treatment [20].
HPLC analysis revealed the absence of alterations in DNA
methylation of a specific locus MyoD1 in ovarian cystade-
nomas, but their presence in both borderline tumors and
carcinomas [21]. These results lend support to the idea
that such changes are early events in ovarian oncogenesis
and emphasize the merit of distinguishing borderline
ovarian neoplasms from cystadenomas, despite their sim-
ilar non-aggressive clinical behavior. Therefore, border-
line tumors of the ovary may be considered a distinct
disease entity.
Telomerase activity in ovarian cancer
Another example of a molecular change shared by both
borderline and malignant but not benign ovarian tumors
is expression of the enzyme telomerase [22]. Activation of
this reverse-transcriptase that synthesizes telomeric
sequences, and is important for DNA replication and
chromosome protection, is strongly associated with can-Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/68
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cer. It is absent from most normal somatic cells and is
present in about 90% of all human tumors. In particular
in the ovary, the first description of differences in telom-
eric instability between normal cells obtained from a tis-
sue with high, site-specific cancer risk due to a genetic
predisposition and similar cells from a control group has
been provided recently [23]. These HOSE cell lines
derived from the ovaries of women with family histories
of breast/ovarian cancer have proven to be a useful culture
model system for studying ovarian oncogenesis. HOSE
cells from cancer-prone individuals, in comparison to
those of individuals at normal risk had reduced growth
potential, increased telomeric instability and shorter tel-
omeres, suggesting that a family history of ovarian malig-
nancy confers increased telomeric instability to the
normal surface epithelium. Moreover, telomeric lengths
in HOSE cells from cancer-prone individuals were shorter
than those found in ovarian cancer, confirming the asso-
ciation of decreased mean telomeric length with malig-
nant transformation [24].
Modeling ovarian cancer
The incessant ovulation hypothesis of ovarian cancer eti-
ology proposed in 1971 suggests that ovulatory rupture
and repair predispose OSE to mutation [25]. It is sup-
ported by epidemiological data that the accumulated
number of menstrual cycles correlates with the risk of
ovarian cancer [26]. The oral contraceptives and preg-
nancy protect against ovarian cancer, probably by a
decrease in lifetime ovulations and/or increasing apopto-
sis of OSE cells, thereby cleansing the ovary of cells with
acquired genetic damage [27,28].
More than twenty years ago, rat OSE was the first OSE of
any species to be established and maintained in tissue cul-
ture. Concurrently, the first demonstration of the suscep-
tibility of OSE to an oncogenic virus was provided [29].
These cells were shown to be transformable by Kirsten
murine sarcoma virus (Ki-MSV) and to produce highly
malignant ovarian tumors in immunosuppressed rats.
Furthermore, for an accurate historical perspective on ani-
mal models of ovarian cancer, the work of Nicosia et al.
on cultured rabbit OSE needs to be highlighted. Their
morphological studies suggested variability in the prolif-
erative activity of OSE during the reproductive life cycle
and role of local factors and/or reproductive patterns in
regulating the growth and development of this crucial
component of the ovary [30,31].
In the 1990s, experimental support for the incessant ovu-
lation hypothesis of ovarian cancer etiology was obtained
by isolating rat OSE (ROSE) cells and subjecting them to
repeated subculture in vitro to mimic the growth of these
cells following ovulation [32,33]. This strategy resulted in
malignant transformation of ROSE as assessed by tumor-
igenicity in ten out of thirty independent attempts. A situ-
ation was provided where independent events leading to
malignant transformation occurred in cells with originally
the same genetic constitution. This not only made availa-
ble related normal/tumor cell pairs, which is an important
asset when techniques of molecular biology are applied to
uncover genetic differences associated with malignant ver-
sus normal cells, but also gave the opportunity to deter-
mine the frequency of the same genetic event in multiple
independent transformants. Using ROSE model, the Lost
On Transformation 1 (LOT1), a growth-suppressor gene
involved in EGFR signaling pathway that encodes a
nuclear zinc-finger protein was discovered. Moreover, by
the technique of genome scanning, the cathepsin B gene
was found to be amplified and/or overexpressed in malig-
nantly transformed ROSE cells. There is evidence suggest-
ing involvement of these genes in human ovarian
oncogenesis [34,35].
Genes associated with early ovarian cancer
In conjunction with the rat in vitro model of ovarian can-
cer, consolidative suppression subtractive hybridization
(CSSH) has been developed and applied to look for gene
expression differences between normal and transformed
cells [36]. Cellular retinol-binding protein 1 (CRBP1),
gene that was found to be down-regulated in this model,
is considered critical to vitamin A (retinol) metabolism. A
recent report by Kuppumbatti et al. indicated that altera-
tions in retinol metabolism could be an early event in
breast oncogenesis [37]. This information and the finding
that treatment with fenretinide, a vitamin A derivative,
prevented the occurrence of ovarian cancers in women
[38] provided the basis to examine expression of CRBP1
in the context of human ovarian cancer [39]. Vitamin A
and derivatives have well-established roles in cancer pre-
vention and treatment [6] and many studies have revealed
the inverse association between ovarian cancer risk and
vitamin A intake [40,41], however the mechanism of this
association is still unclear. Analysis of microdissected
human serous ovarian cancers has shown the loss of
CRBP1 expression in one-third of cases, which is compa-
rable with the in situ hybridization breast cancer study
[37], and with the loss of other genes in ovarian cancer
[12]. This appears to be an early event in human ovarian
oncogenesis, since there was no statistically significant dif-
ference in the loss of CRBP1 expression between histolog-
ical grades or clinical stages of disease in analyzed
samples. Described change in the ability of cells to metab-
olize vitamin A could have implications with regard to
ovarian cancer initiation and/or progression [36,39]. Nev-
ertheless, the study of CRBP1 in ovarian cancer has dem-
onstrated how the novel technology of laser capture
microdissection can improve the quality of the molecular
analysis by eliminating contamination with stromal, vas-Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/68
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cular and inflammatory cells that are often present in EOC
specimens, and by isolating pure populations of ovarian
malignant cells. In the future, results obtained using laser
capture microdissection may allow for better identifica-
tion of early events in ovarian oncogenesis and the
advancement of therapeutic tools.
DOC2/Dab2 is a candidate tumor-suppressor gene that
negatively regulates Ras-mediated cell growth and is
thought to function in epithelial cell positioning control.
Immunohistochemical analysis has shown that the
expression of Dab2 is lost in 80% of ovarian carcinomas
but this loss did not correlate with tumor grade [42]. Dab2
inactivation has been proposed to be an early event in
ovarian oncogenesis enabling the basement membrane-
independent and disorganized proliferation of tumor
cells [43]. Comprehensive histological analysis has also
suggested loss of the basement membrane as an early
event in the preneoplastic transformation of HOSE and in
the early stages of tumorigenesis before tumor invasion
and metastasis [44].
It has been previously reported that activation and overex-
pression of BTAK/Aurora-A gene is more frequent in early-
stage/low-grade ovarian tumors [45]. BTAK/Aurora-A is a
serine/threonine protein kinase, which is essential for
chromosome segregation and centrosome functions.
Immunohistochemical analysis has showed its preferen-
tial expression in less invasive ovarian tumors suggesting
that alterations of BTAK/Aurora-A could be an early event
in human ovarian oncogenesis and play an important role
in development of a subset of ovarian cancers.
Mutations of K-ras oncogene are detected most frequently
in mucinous adenocarcinomas but rarely in other com-
mon epithelial tumors of the ovary and therefore may be
considered a biomarker of this histological subtype [46].
Studies have suggested not only a correlation to histolog-
ical subtype, but also association of K-ras mutation with
early steps in the progression of mucinous ovarian tumors
[47,48]. Mutations of K-ras occur more frequently in bor-
derline than in malignant ovarian serous carcinomas and
they differ between these two categories of ovarian neo-
plasia [49]. According to Ortiz et al., serous borderline
tumors arise through a different molecular pathway than
invasive serous carcinomas and these lesions are perhaps
unrelated [50].
As indicated earlier, problems encountered in the study of
surface epithelium as the source of ovarian cancer are
manifold. Normal OSE does not have any tissue-specific
differentiation markers that would aid in the identifica-
tion of alterations that precede the development of overt
ovarian cancer [51]. During human ovarian oncogenesis,
morphologically simple OSE transforms into highly com-
plex histological structures similar to Müllerian duct-
derived epithelia. This is opposite to majority of other epi-
thelial malignant tumors that during neoplastic transfor-
mation become less differentiated than the epithelium of
their origin. This abnormal differentiation of OSE is asso-
ciated with expression of E-cadherin, a cell-adhesion mol-
ecule acting as an epithelial differentiation marker and
inducer of epithelial differentiation, which is not present
in normal OSE [52]. In carcinomas other then ovarian, E-
cadherin is frequently lost, suggesting possible tumor-sup-
pressor role. In ovarian carcinoma, following the expres-
sion in primary tumors, the subsequent loss of E-cadherin
plays a role in late-stage ovarian metastasis. Experimental
data indicate that expression of E-cadherin is an early event
in ovarian oncogenesis. It initiates early preneoplastic
changes by giving OSE cells a more complex epithelial
phenotype [53]. Similarly, hepatocyte growth factor and
its receptor Met (HGF-Met) may also play a role in early
stages of ovarian oncogenesis according to a study in
HOSE cells obtained from women with family histories of
breast/ovarian cancer [54].
Technological advances in the study of early 
ovarian cancer
A variety of molecular biology and high-throughput tech-
niques are currently being used in order to analyze ovar-
ian tumor tissues and cell lines. Spectral karyotyping,
heterozygosity (LOH) and comparative genomic hybridi-
zation (CGH) techniques were used to look for chromo-
somal gains and/or losses and translocations in genomic
structure of ovarian tumors. Those studies have shown
that early-stage ovarian cancers have a smaller number of
genetic changes than late-stage cases [55,56]. The discov-
ery of frequent allelic losses for a specific chromosome
location suggests that a tumor-suppressor gene for the
malignancy in question maps closely to the locus being
studied. It has been reported that LOH on chromosomes
7p, 7q, 9p and 11q [57], 13q and 17p [58] is an early
event in ovarian tumorigenesis. Borderline tumors have
similar patterns of LOH to that of early-stage malignant
ovarian tumors, indicating inactivation of the same set of
tumor-suppressor genes in the development of malignant
and borderline forms [57]. Karyotypic abnormalities in
ovarian cancer are very complex and difficult to interpret
because of the advanced-stage of disease in most surgical
specimens under analysis.
Techniques such as differential display, suppression sub-
tractive hybridization, cDNA microarray and serial analy-
sis of gene expression (SAGE) are used to examine gene
expression profiles by comparing ovarian tumor and nor-
mal tissues or cell lines. Clinical stage or extent of disease
at diagnosis is one of the most important prognostic fac-
tors in ovarian cancer [59]. It has been reasoned that if
stage I disease is a precursor of advanced ovarian cancer,Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/68
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comparing early- (stage I/II) and late-stage (stage III/IV)
tumor specimens for changes in gene expression and iden-
tifying molecular differences between them should reveal
biomarkers that are hallmarks of early disease and targets
for early diagnosis and/or chemotherapeutic treatments
[39,56,60,61].
Molecular profiling of ovarian cancer is dependent on sev-
eral factors including age, sex, ethnicity and genetic back-
ground of a given patient, as well as on histological
features, grade and stage of disease in the tissue samples
analyzed. The investigations that have compared EOC's
with sex cord-stromal or germ cell tumor samples have led
to discrepancy in explanation of the significance of an
individual gene and its potential role in early ovarian
oncogenesis. Therefore, it is necessary to consider all these
variables in order to identify molecular pathways and
genes leading to ovarian cancer and to determine if each
histological subtype evolves as a result of a separate set of
molecular alterations. Additionally, heterogeneity of ovar-
ian cancer can complicate the interpretation of gene
expression studies. Thus, sample selection is another
important issue and recently developed technique of laser
capture microdissection can be used to isolate a defined
cell population from specific areas of ovarian tissue [39].
While large data sets are obtained and analyzed, gene
expression patterns become apparent, such as groups of
genes coordinately up-regulated in ovarian cancer [62].
Additionally, studies of great numbers of EOC specimens
have allowed researchers to decrease the complexity of
cDNA microarrays by eliminating large subsets of genes
that are not expressed or whose expression does not vary
in EOC's as compared to normal ovarian tissue [63].
Molecular profiling of EOC's will significantly improve
our current understanding of early ovarian oncogenesis
and of the individual histological subtypes of EOC's.
Large-scale analysis of cellular protein profiles of normal
and tumor tissues are also being utilized to reveal quanti-
tative changes in expression and post-translational modi-
fications of proteins that can be important hallmarks of
early ovarian cancer. Surface-enhanced laser desorption
ionization time-of-flight (SELDI-TOF) analysis and
matrix-assisted laser desorption ionization time-of flight
(MALDI-TOF) technology have the potential to distin-
guish patterns of alterations in thousands of small pro-
teins (<20 kd). When linked to computer algorithms,
SELDI-TOF can identify a pattern of protein changes in
serum with high specificity and sensitivity for early ovar-
ian cancer [64].
Conclusion
This review summarized molecular and genetic studies of
early ovarian oncogenesis. It presented problems associ-
ated with studying this process, and emphasized the una-
vailability of early ovarian tumors and the significance of
the OSE as the source of ovarian cancer. The review
addressed the question as to whether ovarian cancer trails
the multistep progression model of oncogenesis as origi-
nally described in colorectal cancer. It appears valid, based
on experimental data, that preneoplasia precedes overt
disease as in other solid tumor types. There has been also
some controversy as to whether ovarian cancer originates
from the surface epithelium or secondary Müllerian sys-
tem. Based on the experimental induction of malignant
transformation in rat, mouse, and human OSE, it is
assumed that ovarian cancer develops from the surface
epithelium. With the advancement of molecular biology
methods, large amount of data has been produced related
to gene expression and genetic abnormalities in ovarian
cancer. However, in order to prove causality of a candidate
gene to some aspect of the diseases phenotype, generation
of mouse models of ovarian cancer by transgenesis will be
required. In the meantime, HOSE cell lines, especially
ones derived from the ovaries of women with family his-
tories of breast/ovarian cancer, continue to serve as a reli-
able, convenient, and clinically relevant model system for
further delineation of molecular pathways involved in the
early stages of ovarian oncogenesis. In summary, any
advance in our understanding of early events in ovarian
neoplastic progression will only come from the applica-
tion of modern techniques and analyses, such as differen-
tial display, comparative genomic hybridization, laser
capture microdissection, suppression subtractive hybridi-
zation, serial analysis of gene expression and cDNA
microarray, which provide a more sophisticated approach
than that allowed by purely morphological methods.
Consequently improved knowledge about molecular
events implicated in early stages of ovarian oncogenesis
will provide a rational basis for management of ovarian
cancer in the near future.
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